Boston, MA -- (SBWIRE) -- 09/09/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: (Dean Foods Company (NYSE:DF), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), First Industrial Realty Trust, Inc. (NYSE:FR), Keryx Biopharmaceuticals (NASDAQ:KERX)
Dean Foods Company (NYSE:DF) shares declined 1.32% to $18.62. The company on August 26 announced the effectiveness of its 1-for-2 reverse stock split of issued Dean Foods common stock, which became effective at 4:15PM Eastern Time today. Dean Foods common stock will begin trading on a split-adjusted basis on the New York Stock Exchange (NYSE) at the opening of trading tomorrow, August 27, 2013.
Also, Dean Foods reiterated its financial guidance for the third quarter of 2013 while updating the figures to account for the impact of the reverse stock split.
How Should Investors Trade DF After The Recent Volatility? Get Free Report Here
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares climbed 4.20% to $3.97. The company on August 22 announced that the British Journal of Cancer has published the paper "A Multinational Phase 2 Study of Nanoliposomal Irinotecan Sucrosofate (PEP02, MM-398) for Patients with Gemcitabine-Refractory Metastatic Pancreatic Cancer" in its latest issue. The Phase 2 study evaluated MM-398 (liposomal irinotecan sucrosulfate) monotherapy in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy.
How Should Investors Trade MACK After The Recent Volatility? Get Free Report Here
First Industrial Realty Trust, Inc. (NYSE:FR) shares jumped 2.24% and closed at $15.51 in the last trading session. The company on August 7 announced that its board of directors declared a common stock dividend of $0.085 per share/unit for the quarter ending September 30, 2013 payable on October 21, 2013 to stockholders of record on September 30, 2013.
Is FR A Good Buy After The Recent Price Movement? Find Out Here
Keryx Biopharmaceuticals (NASDAQ:KERX) shares gained 2.08% to $9.32. The company will be presenting at the following upcoming healthcare investor conferences: RODMAN & RENSHAW 15th ANNUAL GLOBAL INVESTMENT CONFERENCE on Monday, September 9, 2013 at 10:00am ET and STIFEL NICOLAUS 2013 HEALTHCARE CONFERENCE on Thursday, September 12, 2013 at 3:50pm ET.
Additionally, the company company on August 8 announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Zerenex™ (ferric citrate coordination complex), the Company's drug candidate for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on dialysis.
Is KERX A Strong Buy? Get Advantage Of Our Free Trend Analysis Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t sure you won’t be disappointed.
http://winstonsmallcap.com/and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)